Published in J Immunother on April 01, 2012
Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol (2014) 1.61
Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2013) 0.95
Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells. Semin Oncol (2016) 0.84
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. Front Immunol (2016) 0.78
Impact of fibroblast activation protein on osteosarcoma cell lines in vitro. Oncol Lett (2014) 0.77
Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors. Cancer Immunol Immunother (2014) 0.76
Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther (2016) 0.75
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med (1996) 9.31
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A (2002) 8.72
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 8.07
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst (1994) 7.20
Differential T cell costimulatory requirements in CD28-deficient mice. Science (1993) 6.93
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest (2008) 6.15
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med (1999) 6.09
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother (2001) 5.83
Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med (1990) 5.27
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol (2004) 4.73
Cortical constriction during abscission involves helices of ESCRT-III-dependent filaments. Science (2011) 4.26
A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science (2002) 4.21
Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol (2005) 3.89
Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev (2009) 3.56
B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity (1997) 3.22
Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol (1999) 3.10
Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol (2010) 2.44
Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res (2004) 1.74
Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol (2003) 1.53
IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol (2009) 1.43
Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev (2009) 1.39
CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A (2002) 1.34
Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action. J Exp Med (1990) 1.28
TRAF proteins in CD40 signaling. Adv Exp Med Biol (2007) 1.27
Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther (2003) 1.22
CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination. Proc Natl Acad Sci U S A (2001) 1.22
A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin Cancer Res (2003) 1.10
The Janus faces of CD40 in cancer. Semin Immunol (2009) 0.98
Adoptive therapy using antigen-specific T-cell clones. Cancer J (2010) 0.97
Biology and clinical applications of CD40 in cancer treatment. Semin Oncol (2010) 0.96
Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3. Am J Transplant (2003) 0.93
T-cell adoptive immunotherapy of metastatic renal cell carcinoma. Urology (1999) 0.90
Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion. Semin Oncol (2004) 0.83